非小细胞肺癌骨转移临床特点探讨

为探讨非小细胞肺癌骨转移的临床特点，对178例非小细胞肺癌患者的骨转移情况和治疗预后进行统计分析。结果显示肺癌骨转移率为48．3％；腺癌骨转移率最高，占59．5％；细胞分化程度越低，骨转移率越高（P〈0．01）；Ⅲ～Ⅳ期骨转移率明显高于Ⅰ～Ⅱ期（P〈0．01）；骨转移后1年生存率为26．7％，中位生存期为8个月。骨转移后采取放、化疗为主的综合治疗可明显减轻症状，延长生存时间。表明非小细胞肺癌骨转移临床常见，转移率与病理类型、分化程度、临床分期均有关系。晚期肺癌骨转移患者综合治疗可提高生存质量和生存期。

A STUDY ON CLINICAL CHARACTERISTICS OF BONE METASTASIS OF NON-MICROCYTIC PULMONARY CARCINOIMA

A statistical analysis was made on the bone metastasis and the treatment prognosis of 178 cases of non-microcystic pulmonary carcinoma (NMCPC) in order to study the clinical characteristics of the bone metastasis of NMCPC. The results showed the bone metastatic rate of lung carcinoma was 48.3 %; the bone metastatic rate of adenocarcinoma was 59.4 %, being the highest; the lower the cell differentiation, the higher the bone metastatic rate (P < 0.01); the bone metastatic rate of III- or IV-staged NMCPC was significantly higher than that of the I- or II-staged; the one-year survival rate after bone metastasis was 26.7 %; the middle survival time was 8 months; the comprehensive treatment taking the radiotherapy and chemotherapy as the main could significantly alleviate the symptoms and prolong the survival, suggesting that NMCPC is clinically common; the bone metastatic rate is related to the pathological type, differentiation degree and clinical stage; the comprehensive treatment after the bone metastasis could significantly improve the living quality and survival time of the cases of late-staged lung carcinoma.